

WHAT IS CLAIMED IS:

1. A topical patch preparation of a delayed-type hypersensitivity inducer, said
5 preparation comprising:
an adhesive gel composition comprising a delayed-type hypersensitivity inducer; and
a support.
2. The topical patch preparation according to Claim 1, wherein said delayed-type
10 hypersensitivity inducer is 1-Chloro-2,4-Dinitrobenzene (DNCB).
3. The topical patch preparation according to Claim 2, wherein said DNCB is present in
said adhesive gel composition in an amount ranging from about 0.01 to 10.0 % (w/w).
- 15 4. The topical patch preparation of Claim 1, wherein said adhesive gel composition
comprises:
a water-soluble polymer gel;
water; and
a water retaining agent.
- 20 5. The topical patch preparation according to Claim 4, wherein said water is present in
an amount ranging from about 10 to 80 % (w/w).
6. The topical patch preparation according to Claim 1, wherein said adhesive gel
25 composition has a pH ranging from about 4.0 to 7.0.
7. The topical patch preparation according to Claim 1, wherein said adhesive gel
composition further comprises an organic solvent.
- 30 8. The topical patch preparation according to Claim 7, wherein said organic solvent is
selected from the group consisting of n-methyl-2-pyrrolidone, polyethylene glycol and
crotamiton and combinations thereof.

9. A topical patch preparation comprising:

(a) an adhesive gel composition having a pH ranging from about 4.0 to 7.0 and comprising:

- (i) DNCB in an amount ranging from about 0.01 to 10.0 % (w/w);
- (ii) a water-soluble polymer gel;
- (iii) water in an amount ranging from about 10 to 80 % (w/w); and
- (iv) a water retaining agent; and

(b) a support.

10. The topical patch preparation according to Claim 9, wherein said DNCB is present in an amount ranging from about 0.1 to 5.0 % (w/w).

11. The topical patch preparation according to Claim 10, wherein said DNCB is present in an amount ranging from about 0.2 to 3.0% (w/w).

12. The topical patch preparation according to Claim 9, wherein said water is present in an amount ranging from about 20 to 70% (w/w).

13. The topical patch preparation according to Claim 12, wherein said water is present in an amount ranging from about 30 to 60 % (w/w).

14. The topical patch preparation according to Claim 9, wherein said pH ranges from about 4.0 to 6.0.

15. The topical patch preparation according to Claim 14, wherein said adhesive gel composition further comprises an organic solvent.

16. The topical patch preparation according to Claim 15, wherein said organic solvent is selected from the group consisting of n-methyl-2-pyrrolidone, polyethylene glycol, and crotamiton and combinations thereof.

17. A topical patch preparation comprising:
- (a) an adhesive gel composition having a pH ranging from about 4.0 to 6.0 and comprising:
- (i) DNCB in an amount ranging from about 0.2 to 3.0 % (w/w);
 - (ii) a water-soluble polymer gel;
 - (iii) water in an amount ranging from about 30 to 60 % (w/w);
 - (iv) a water retaining agent; and
 - (v) an organic cosolvent selected from the group consisting of n-methyl-2-pyrrolidone, polyethylene glycol and crotamiton and combinations thereof;
- (b) a support.

18. A method of delivering a delayed-type hypersensitivity inducer to a subject, said method comprising:

- (a) applying a topical patch preparation comprising:
- (i) an adhesive gel composition comprising said delayed-type hypersensitivity inducer; and
 - (b) a support;
- to a skin surface of said subject; and
- (b) maintaining said topical patch preparation on said skin surface for a period of time sufficient for said delayed-type hypersensitivity inducer to be delivered to said subject.

19. The method according to Claim 18, wherein said delayed-type hypersensitivity inducer is DNCB.

20. The method according to Claim 19, wherein said DNCB is present in said adhesive gel composition in an amount ranging from about 0.01 to 10.0 % (w/w).

21. The method according to Claim 18, wherein said adhesive gel composition comprises:

- a water-soluble polymer gel;
- water; and

a water retaining agent.

22. The method according to Claim 21, wherein said adhesive gel composition further comprises an organic solvent.

5

23. The method according to Claim 22, wherein said organic solvent is selected from the group consisting of n-methyl-2-pyrrolidone, polyethylene glycol and crotonamite and combinations thereof.

10 24. The method according to Claim 18, wherein said method is a method of treating an immunocompromising disease.

25. A method of treating a host suffering from an immunocompromising disease, said method comprising:

5 (a) applying a topical patch preparation comprising:

(i) an adhesive gel composition comprising an effective amount of a delayed-type hypersensitivity inducer; and

(b) a support;

to a skin surface of said subject; and

20 (b) maintaining said topical patch preparation on said skin surface for a period of time sufficient for said effective amount of delayed-type hypersensitivity inducer to be delivered to said subject.

25 26. The method according to Claim 25, wherein said delayed-type hypersensitivity inducer is DNCB.

27. The method according to Claim 26, wherein said DNCB is present in said adhesive gel composition in an amount ranging from about 0.01 to 10.0 % (w/w).

30 28. The method according to Claim 25, wherein said adhesive gel composition comprises:

a water-soluble polymer gel;

B, F & F Ref: TEIK-004

Teikoku Ref:

F:\DOCUMENT\TEIK\004\patent application.doc

water; and
a water retaining agent.

29. The method according to Claim 28, wherein said adhesive gel composition further
5 comprises an organic solvent.

30. The method according to Claim 29, wherein said organic solvent is selected from the
group consisting of n-methyl-2-pyrrolidone, polyethylene glycol and crotamiton and
combinations thereof.

31. The method according to Claim 25, wherein said immunocompromising disease is an
HIV infection.

32. ✓ A method of treating a host suffering from an HIV infection, said method
15 comprising:

- (a) applying a topical patch preparation comprising:
 - (i) an adhesive gel composition comprising an effective amount of
DNCB; and
 - (b) a support;
20 to a skin surface of said subject; and
- (b) maintaining said topical patch preparation on said skin surface .

33. The method according to Claim 32, wherein said DNCB is present in said adhesive
gel composition in an amount ranging from about 0.01 to 10.0 % (w/w).

34. The method according to Claim 32, wherein said adhesive gel composition
comprises:

a water-soluble polymer gel;
water; and
30 a water retaining agent.

35. The method according to Claim 34, wherein said adhesive gel composition further comprises an organic solvent.

36. The method according to Claim 35, wherein said organic solvent is selected from the group consisting of n-methyl-2-pyrrolidone, polyethylene glycol and crotamiton and combinations thereof.

37. A kit for use in transdermal delivery of a delayed-type hypersensitivity inducer to a subject in need thereof, said kit comprising:

- (a) a topical patch preparation comprising:
 - (i) an adhesive gel composition comprising an effective amount of a delayed-type hypersensitivity inducer; and
 - (ii) a support; and
- (b) instructions for using said preparation.

38. The kit according to Claim 37, wherein said kit comprises a plurality of said topical patch preparations.

39. The kit according to Claim 38, wherein said plurality of topical patch preparations are present in separate containers.

40. The kit according to Claim 39, wherein said separate containers are sealed pouches.